drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy (gene-modified cellular therapy)
drug_description
Autologous CD19-directed CAR T-cell therapy composed of genetically modified T cells that mediate CAR-dependent recognition and cytotoxic killing of CD19-positive B-cell lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lisocabtagene Maraleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-directed chimeric antigen receptor; upon binding CD19 on malignant B cells, the CAR activates T-cell effector functions, leading to proliferation and perforin/granzyme-mediated cytotoxic killing of CD19-positive cells.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT06313996